Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic ...

Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in ...

Gilead’s (NASDAQ:GILD) Kite unit reported positive results from a five-year follow-up of a Phase 2 study for its cell therapy Yescarta in certain patients with non-Hodgkin lymphoma, or NHL.

The Scottish Medicines Consortium has backed NHS funding for Gilead’s CAR-T therapy Yescarta for B-cell lymphomas, a few months after it was given the okay south of the border. Yescarta ...

Priced at $373,000 per patient, Gilead’s Yescarta (axicabtagene ciloleucel) has just been approved by the FDA for adults with relapsed or refractory large B-cell lymphoma after two or more lines ...

Galapagos' CAR-T therapy GLPG5101 shows promising efficacy but has limited durability data and small patient samples compared to Yescarta. Phase 1 safety concerns have improved in Phase 2 ...

Curocell launches Limcato, South Koreas first domestic CAR-T cancer therapy Curocell introduces first local CAR-T therapy, ...

In Q1 2024, Gilead recorded 4% revenue gains from the help of Biktarvy (indicated for HIV-1 infection) and their cell therapy products (e.g., Yescarta). I was also keeping a close eye on seladelpar.

Islands not In hurricane belt Coronavirus: How much have we learned from the experience and lessons of more than a decade? Beijing's 2020 ...

INR:1994. kerala lottery bumper list "Pharmaceutical Speed ​​Reading Club" Many Biogen employees were infected with the new coronavirus, and Pien T ...